| Jack A Abarbanel, DO | |
|
1604 Burtner Rd, Natrona Heights, PA 15065-2845 | |
| (724) 230-3030 | |
| (724) 230-3001 |
| Full Name | Jack A Abarbanel |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 50 Years |
| Location | 1604 Burtner Rd, Natrona Heights, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619947686 | NPI | - | NPPES |
| 0011033160004 | Medicaid | PA | |
| 10921831 | Other | PA | CAQH |
| 192265 | Other | PA | HIGHMARK BS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0203X | Radiology - Therapeutic Radiology | OS003294L (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Pittsburgh Cancer Institute Cancer Services | 6709771587 | 39 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung illness and the third leading cause of death in the United States. Scientists have long believed that inhaling toxic gases and particles from tobacco smoke causes inflammation of the small airways in the lungs, leading to the development of COPD. However, the theory doesn't explain why airway inflammation and disease progression continue even after the patient stops smoking.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.
Patients with excited delirium who are combative, aggressive or agitated before being transported to the hospital or in an emergency department setting require immediate treatment for their safety and others.
› Verified 2 days ago
| Entity Name | Mountain View Cancer Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013984376 PECOS PAC ID: 5597666792 Enrollment ID: O20040120000532 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung illness and the third leading cause of death in the United States. Scientists have long believed that inhaling toxic gases and particles from tobacco smoke causes inflammation of the small airways in the lungs, leading to the development of COPD. However, the theory doesn't explain why airway inflammation and disease progression continue even after the patient stops smoking.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.
Patients with excited delirium who are combative, aggressive or agitated before being transported to the hospital or in an emergency department setting require immediate treatment for their safety and others.
› Verified 2 days ago
| Entity Name | University Of Pittsburgh Cancer Institute Cancer Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427025840 PECOS PAC ID: 6709771587 Enrollment ID: O20040219000811 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung illness and the third leading cause of death in the United States. Scientists have long believed that inhaling toxic gases and particles from tobacco smoke causes inflammation of the small airways in the lungs, leading to the development of COPD. However, the theory doesn't explain why airway inflammation and disease progression continue even after the patient stops smoking.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.
Patients with excited delirium who are combative, aggressive or agitated before being transported to the hospital or in an emergency department setting require immediate treatment for their safety and others.
› Verified 2 days ago
| Entity Name | Fayette Oncology Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003817958 PECOS PAC ID: 1052201589 Enrollment ID: O20040318000539 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung illness and the third leading cause of death in the United States. Scientists have long believed that inhaling toxic gases and particles from tobacco smoke causes inflammation of the small airways in the lungs, leading to the development of COPD. However, the theory doesn't explain why airway inflammation and disease progression continue even after the patient stops smoking.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.
Patients with excited delirium who are combative, aggressive or agitated before being transported to the hospital or in an emergency department setting require immediate treatment for their safety and others.
› Verified 2 days ago
| Entity Name | Indiana Healthcare Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578523429 PECOS PAC ID: 5294723359 Enrollment ID: O20040927000404 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung illness and the third leading cause of death in the United States. Scientists have long believed that inhaling toxic gases and particles from tobacco smoke causes inflammation of the small airways in the lungs, leading to the development of COPD. However, the theory doesn't explain why airway inflammation and disease progression continue even after the patient stops smoking.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.
Patients with excited delirium who are combative, aggressive or agitated before being transported to the hospital or in an emergency department setting require immediate treatment for their safety and others.
› Verified 2 days ago
| Entity Name | Upmc/conemaugh Cancer Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326015538 PECOS PAC ID: 7618912494 Enrollment ID: O20050622000702 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung illness and the third leading cause of death in the United States. Scientists have long believed that inhaling toxic gases and particles from tobacco smoke causes inflammation of the small airways in the lungs, leading to the development of COPD. However, the theory doesn't explain why airway inflammation and disease progression continue even after the patient stops smoking.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.
Patients with excited delirium who are combative, aggressive or agitated before being transported to the hospital or in an emergency department setting require immediate treatment for their safety and others.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jack A Abarbanel, DO 2 Hot Metal St, Quantum One, N431, Pittsburgh, PA 15203-2348 Ph: (412) 432-5806 | Jack A Abarbanel, DO 1604 Burtner Rd, Natrona Heights, PA 15065-2845 Ph: (724) 230-3030 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung illness and the third leading cause of death in the United States. Scientists have long believed that inhaling toxic gases and particles from tobacco smoke causes inflammation of the small airways in the lungs, leading to the development of COPD. However, the theory doesn't explain why airway inflammation and disease progression continue even after the patient stops smoking.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.
Patients with excited delirium who are combative, aggressive or agitated before being transported to the hospital or in an emergency department setting require immediate treatment for their safety and others.
› Verified 2 days ago
Prabha Bansal, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 1604 Burtner Rd, Natrona Heights, PA 15065 Phone: 724-230-3030 Fax: 724-230-3001 | |
Bart J Friedman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1301 Carlisle St, Dept Of Radiology, Natrona Heights, PA 15065 Phone: 724-334-4774 Fax: 724-334-4776 | |
Surendra V Pawar, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1301 Carlisle St, Dept Of Radiology, Natrona Heights, PA 15065 Phone: 721-334-4774 Fax: 724-334-4776 | |
Dr. Maddie Sharma, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1604 Burtner Rd, Natrona Heights, PA 15065 Phone: 724-230-3011 Fax: 724-230-3004 | |
Edward R Scheid, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1301 Carlisle Street, Dept Of Radiology, Natrona Heights, PA 15065 Phone: 724-334-4774 Fax: 724-334-4776 | |
Janet H Tabas, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1301 Carlisle Street, Dept Of Radiology, Natrona Heights, PA 15065 Phone: 724-334-4774 Fax: 724-334-4776 |